Jaime Sanz at Universitat de Valencia Facultad de Medicina - Research Interests, Publications & Academic Profile

Jaime Sanz

Profesor asociado asistencial

Universidad Católica de Valencia Facultad de Medicina

Spain

This profile is automatically generated from trusted academic sources.

Google Scholar

ORCID

How do I reach out?

Meet Kite AI

Contact this professor

ORCID

Google Scholar

Research Interests

Immunology

80%

Virology

40%

Hematology

100%

Graft-versus-host Disease

90%

Cancer Therapy

80%

Stem Cell Transplantation

80%

Transplantation

70%

Ask ApplyKite AI

Start chatting

How can you help me contact this professor?

What are this professor's research interests?

How should I write an email to this professor?

Articles20

Outcomes for patients with EBV-positive PTLD post-allogeneic HCT after failure of rituximab-containing therapy

Article Link

Year:

2024

Haploidentical stem cell donor choice for patients with acute myeloid leukemia: a study from the ALWP of the EBMT.

Article Link

Year:

2024

Posttransplant cyclophosphamide versus anti-thymocyte globulin versus combination for graft-versus-host disease prevention in haploidentical transplantation for adult acute myeloid leukemia: A report from the European Society for Blood and Marrow Transplantation Acute Leukemia Working Party

Article Link

Year:

2024

Younger unrelated donors may be preferable over HLA match in the PTCy era: a study from the ALWP of the EBMT

Article Link

Year:

2024

Cord blood transplantation for AML: Comparable LFS in patients with de novo versus secondary AML in CR1, an ALWP/EBMT study

Article Link

Year:

2024

Immune reconstitution after single-unit umbilical cord blood transplantation using anti-thymoglobulin and myeloablative conditioning in adults with hematological malignancies

Article Link

Year:

2024

Ofatumumab as part of reduced intensity conditioning in high risk B-cell lymphoma patients: final long-term analysis from a prospective multicenter Phase-II Trial

Article Link

Year:

2024

Outcome of Human Parainfluenza Virus infection in allogeneic stem cell transplantation recipients: possible impact of ribavirin therapy

Article Link

Year:

2024

Post-Transplantation Cyclophosphamide-Based Graft-versusHost Disease Prophylaxis in HLA-Matched and Haploidentical Donor Transplantation for Patients with Hodgkin Lymphoma: A Comparative Study of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation

Article Link

Year:

2024

Thiotepa-Based Regimens Are Valid Alternatives to Total Body Irradiation-Based Reduced-Intensity Conditioning Regimens in Patients with Acute Lymphoblastic Leukemia: A Retrospective Study on Behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation

Article Link

Year:

2024

Multicenter Long-Term Follow-Up of Allogeneic Hematopoietic Cell Transplantation with Omidubicel: A Pooled Analysis of Five Prospective Clinical Trials

Article Link

Year:

2023

Long-term outcome of second allogeneic hematopoietic stem cell transplantation (HSCT2) for primary graft failure in patients with acute leukemia in remission: A study on behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation

Article Link

Year:

2023

Extracorporeal Photopheresis in Graft-versus-Host Disease

Article Link

Year:

2023

Etoposide plus cytarabine versus cyclophosphamide or melphalan in busulfan-based preparative regimens for autologous stem cell transplantation in adults with acute myeloid leukemia in first complete remission: a study from the Acute Leukemia Working Party of the EBMT

Article Link

Year:

2023

Outcomes of graft failure after umbilical cord blood transplantation in acute leukemia: a study from Eurocord and the Acute Leukemia Working Party of the EBMT

Article Link

Year:

2023

Post‐transplant cyclophosphamide in acute leukemia patients receiving more than 5/10 HLA‐mismatched allogeneic hematopoietic cell transplantation from related donors: A study on behalf of the ALWP of the EBMT

Article Link

Year:

2023

Post-transplant cyclophosphamide in acute leukemia patients receiving more than 5/10 HLA-mismatched allogeneic hematopoietic cell transplantation from related donors: A study on behalf of the ALWP of the EBMT

Article Link

Year:

2023

Total body irradiation plus fludarabine versus busulfan plus fludarabine as a myeloablative conditioning for adults with acute myeloid leukemia treated with allogeneic hematopoietic cell transplantation. A study on behalf of the Acute Leukemia Working Party of the EBMT

Article Link

Year:

2023

Outcomes of subsequent neoplasms after umbilical cord blood transplantation in Europe

Article Link

Year:

2023

Axicabtagene ciloleucel compared to tisagenlecleucel for the treatment of aggressive B-cell lymphoma

Article Link

Year:

2023

Collaborators6

William Ying Khee Hwang

Professor and Chair

Duke-NUS Medical School

SINGAPORE

Per Ljungman

Karolinska University Hospital

SWEDEN

Suhag Parikh

Emory University

UNITED STATES

Didier Blaise

Professor of Medicine

Aix-Marseille University

FRANCE

Thomas Pabst

SWITZERLAND

Jurgen Kuball

UMC Utrecht

NETHERLANDS

How do I reach out?

Meet Kite AI